NCT01432379已完成不适用
BOTOX® Prophylaxis in Patients With Chronic Migraine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 1,168
- 主要终点
- Incidence Rate of Dysphagia
研究概览
简要总结
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of chronic migraine
- •Willing to use BOTOX® as preventative treatment for migraine
排除标准
- 未提供
结局指标
主要结局
Incidence Rate of Dysphagia
时间窗: 64 weeks
Incidence rates are reported for subjects with events per 1,000 person-months and are based on the first reported occurrence of dysphagia from study enrollment up to 64 weeks. Dysphagia is difficulty or discomfort swallowing.
次要结局
- Incidence Rate of Intractable Migraine(64 weeks)
研究者
相似试验
已完成
不适用
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive BladderUrinary IncontinenceUrinary Bladder, OveractiveNCT02161159Allergan515
已完成
不适用
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial PainChronic MigraineNCT03175263University Hospital, Limoges57
已完成
4 期
Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes.Chronic MigraineNCT02436499University of Manitoba12
已完成
不适用
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in BelgiumUrinary IncontinenceNCT02072928Allergan55
已完成
4 期
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown LinesGlabellar Frown LinesNCT01391312Allergan40